Current clinical evidence is insufficient to support HMME–PDT as the first choice of treatment for young children with port wine birthmarks
Lasers in Surgery and Medicine · 2024
DOI: 10.1002/lsm.23779 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Lasers in Surgery and Medicine, 2024. Verfasst von Chao Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, South Carolina, USA. Hauptthemen laut MEDLINE: Photochemotherapy, Port-Wine Stain, Lasers, Dye. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Port wine birthmark (PWB) is a congenital vascular malformation of the skin. Pulsed dye laser (PDL) is the “gold standard” for the treatment of PWB globally. Hematoporphyrin monomethyl ether (HMME or hemoporfin)‐mediated photodynamic therapy (HMME–PDT) has emerged as the first choice for PWB treatment, particularly for young children, in many major hospitals in China during the past several decades.
Aim
To evaluate whether HMME–PDT is superior to PDL by comparing the clinical efficacies of both modalities.
Method
PubMed records were searched for all relevant studies of PWB treatment using PDL (1988−2023) or HMME–PDT (2007−2023). Patient characteristics and clinical efficacies were extracted. Studies with a quartile percentage clearance or similar scale were included. A mean color clearance index (CI) per study was calculated and compared among groups. An overall CI (C 0 ), with data weighted by cohort size, was used to evaluate the final efficacy for each modality.
Result
A total of 18 HMME–PDT studies with 3910 patients in China were eligible for inclusion in this analysis. Similarly, 40 PDL studies with 5094 patients from nine different countries were eligible for inclusion in this analysis. Over 58% of patients in the HMME‐PDT studies were minors (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, South Carolina, USA.
- The Facial Surgery Center and the Hemangioma & Malformation Treatment Center, Charleston, South Carolina, USA.
- Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Dermatology, XiJing Hospital, Xi'an, Shaanxi, China.
- Division of Plastic Surgery, School of Medicine, University of South Carolina, Columbia, South Carolina, USA.
- Division of Plastic Surgery, Prisma Health Medical Group, Columbia, South Carolina, USA.
ORCID-Profile: Chao Gao
Förderung
- NIAMS NIH HHS
Zitieren
APA
Gao, C., Nguyen, V., Hochman, M. L., Gao, L., Chen, E. H., Friedman, H. I., Nelson, J. S., & Tan, W. (2024). Current clinical evidence is insufficient to support HMME–PDT as the first choice of treatment for young children with port wine birthmarks. Lasers in Surgery and Medicine. https://doi.org/10.1002/lsm.23779
Vancouver
Gao C, Nguyen V, Hochman ML, Gao L, Chen EH, Friedman HI, et al. Current clinical evidence is insufficient to support HMME–PDT as the first choice of treatment for young children with port wine birthmarks. Lasers in Surgery and Medicine. 2024. doi:10.1002/lsm.23779
BibTeX
@article{Gao2024,
author = {Gao, Chao and Nguyen, Vi and Hochman, Marcelo L and Gao, Lin and Chen, Elliott H and Friedman, Harold I and Nelson, John Stuart and Tan, Wenbin},
title = {Current clinical evidence is insufficient to support HMME–PDT as the first choice of treatment for young children with port wine birthmarks},
journal = {Lasers in Surgery and Medicine},
year = {2024},
doi = {10.1002/lsm.23779}
}
EUVIMED